Live
- Israel intercepts missile from Yemen, says IDF
- Assam only state to see dip in road accidents: CM Sarma
- MP BJP to celebrate former PM Vajpayee's birth anniversary on Dec 25
- Christmas Eve 2024: Heartwarming Messages To Share With Your Loved Ones
- PM Modi holds brainstorming session with economists in run-up to Budget
- “Telangana Ready to Support AI Technologies That Drive Social Impact,” says Special Chief Secy, Jayesh Ranjan at Woxsen University’s Future Tech Summit 2024
- Hero Motosports Team Rally Announces Squad For Dakar Rally 2025
- Two Men Found Dead In Parked Caravan In Kerala
- Mandhana moves closer to top spot in ODI, T20I rankings
- IND vs AUS Boxing Day Test 2024: Sam Konstas Debuts, Travis Head’s Fitness in Question
GSK, Pfizer get nod for consumer healthcare JV
The Competition Commission on Friday said it has approved the formation of a joint venture for consumer healthcare products by pharmaceutical giants GlaxoSmithKline (GSK) and Pfizer.
New Delhi: The Competition Commission on Friday said it has approved the formation of a joint venture for consumer healthcare products by pharmaceutical giants GlaxoSmithKline (GSK) and Pfizer.
GSK, in December 2018, had said it has reached an agreement with Pfizer to combine their consumer health businesses into a new joint venture (JV) with combined sales of around $12.7 billion (around
Rs 88,900 crore).
In a tweet, the Competition Commission of India (CCI) said it "approves formation of a JV for consumer healthcare products by GSK and Pfizer."
The proposed combination involves acquisition of Pfizer's consumer healthcare business by GSK, and the combination of GSK and Pfizer consumer healthcare business into a global consumer healthcare joint venture under the sole control of GSK, as per a notice submitted to CCI.
